Extremely Preterm Respiratory Outcome Cohort
Multicenter Cohort for Respiratory Outcome of Preterm Infants
1 other identifier
observational
600
1 country
1
Brief Summary
This study examines the respiratory outcomes of preterm infants born at gestational ages less than 29 weeks, spanning from birth to 24 months corrected age. It delves into the intricacies of respiratory function impairment attributable to diverse factors, such as respiratory distress syndrome, bronchopulmonary dysplasia, postnatal corticosteroids, ventilatory support, as well as nutritional aspect during NICU stay. Furthermore, it scrutinizes the incidence of chronic respiratory diseases stemming from these conditions, assessing their long-term impact on respiratory prognosis post-discharge. In addition to respiratory aspects, the research extends its focus to the growth and developmental outcomes of preterm infants. By synthesizing these multifaceted elements, the study aspires to enhance current treatments and preventative measures for respiratory conditions in preterm infants.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2022
CompletedFirst Submitted
Initial submission to the registry
January 16, 2024
CompletedFirst Posted
Study publicly available on registry
December 10, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 28, 2030
December 10, 2024
December 1, 2024
7.8 years
January 16, 2024
December 4, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Postprematurity respiratory disease
1. Severe * ≥2 respiratory hospitalizations, * home supplemental O2 after 3 months or any home mechanical ventilation, * systemic steroid exposure or pulmonary vasodilators, or symptoms despite -inhaled corticosteroid use 2. Mild to moderate * one hospitalization * home oxygen \<3 months corrected age or tracheostomy without ventilation, * any inhaled corticosteroid or bronchodilator exposure, or symptoms in ≥2 questionnaires 3. No/minimal - all other cases 1\. Respiratory medications 2. Hospitalizations for cardiopulmonary cause 3. Coughing, wheezing, or other respiratory symptoms 4. Home technology dependence
12 months of corrected age
Secondary Outcomes (3)
Growth assessment
at 24 months of corrected age
Any delay in developmental scale evaluation
at 24 months of corrected age
Long-term respiratory outcome
at 6 years of corrected age
Study Arms (1)
Respiratory cohort
Preterm infants with a gestational age less than 29 weeks
Interventions
Standard care for preterm infants according to the institutional protocol
Eligibility Criteria
This study is a multicenter cohort study conducted by a total of 7 institutions (Seoul National University Hospital, Severance Hospital, Asan Medical center, Samsung Medical Hospital, Ajou University Hospital, Bundang Seoul National University Hospital, Chonnam National University Hospital) jointly. It includes all preterm infants born at these hospitals from March 2022 to December 2024, who are born at a gestational age of less than 29 weeks and are admitted to the neonatal intensive care unit.
You may qualify if:
- Infants born at gestational age less than 29 weeks with cohort consent obtained within 7 days of birth
You may not qualify if:
- death within 3 days of birth
- severe structural heart defects
- structural abnormalities in the upper airway, lungs, or chest
- congenital anomalies that may impact cardiopulmonary function
- follow-up is difficult until 24 months of age
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Seoul National University Hospitallead
- Asan Medical Centercollaborator
- Samsung Medical Centercollaborator
- Seoul National University Bundang Hospitalcollaborator
- Chonnam National University Hospitalcollaborator
- Severance Hospital, Yonsei University College of Medicinecollaborator
- Ajou University Medical Centercollaborator
Study Sites (1)
Seung Han Shin
Seoul, 110-744, South Korea
Biospecimen
1. Transtracheal aspirate Collection Timing: Immediately after registration, 3(±1) days after the first collection, 14(±2) days after birth, and 28(±2) days after birth. 2. Urine Collection Timing: Immediately after registration, 3(±1) days after the first collection, 14(±2) days after birth, and 28(±2) days after birth.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Seung Han Shin, MD, PhD
Seoul National University Children's Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 16, 2024
First Posted
December 10, 2024
Study Start
June 1, 2022
Primary Completion (Estimated)
February 28, 2030
Study Completion (Estimated)
February 28, 2030
Last Updated
December 10, 2024
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will not share